Selective and brain-penetrant ACSS2 inhibitors target breast cancer brain metastatic cells

Breast cancer brain metastasis (BCBM) typically results in an end-stage diagnosis and is hindered by a lack of brain-penetrant drugs. Tumors in the brain rely on the conversion of acetate to acetyl-CoA by the enzyme acetyl-CoA synthetase 2 (ACSS2), a key regulator of fatty acid synthesis and protein...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Frontiers in pharmacology Jg. 15; S. 1394685
Hauptverfasser:	Esquea, Emily M., Ciraku, Lorela, Young, Riley G., Merzy, Jessica, Talarico, Alexandra N., Ahmed, Nusaiba N., Karuppiah, Mangalam, Ramesh, Anna, Chatoff, Adam, Crispim, Claudia V., Rashad, Adel A., Cocklin, Simon, Snyder, Nathaniel W., Beld, Joris, Simone, Nicole L., Reginato, Mauricio J., Dick, Alexej
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	Switzerland Frontiers Media S.A 16.05.2024
Schlagworte:	acetate acetyl-CoA brain metastasis breast cancer cancer metabolism Pharmacology acetate computational-aided drug design font: italic formatted: left ACSS2 breast cancer acetyl-CoA brain metastasis cancer metabolism
ISSN:	1663-9812, 1663-9812
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!